BriaCell Therapeutics Corp (NASDAQ:BCTX) shares are trading higher on Wednesday after the company announced it is expanding its breast cancer platform into prostate, melanoma and lung cancers.
The expansion includes Bria-Pros for prostate cancer, Bria-Mel for melanoma and Bria-Lung for lung cancer and the company anticipates commencing clinical trials for these therapies in 2022.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.
At the time of publication, shares of BriaCell Therapeutics were trading 18.6% higher at $7.15. The stock has a 52-week low of $2.81 and a 52-week high of $9.00.
